2022
Clinical and Demographic Differences in the Willingness to use Self-Administered At-Home COVID-19 Testing Measures among Persons with Opioid use Disorder
Mistler CB, Sullivan M, Wickersham JA, Copenhaver MM, Shrestha R. Clinical and Demographic Differences in the Willingness to use Self-Administered At-Home COVID-19 Testing Measures among Persons with Opioid use Disorder. Substance Use & Addiction Journal 2022, 43: 708-712. PMID: 35100084, PMCID: PMC9725184, DOI: 10.1080/08897077.2021.2007511.Peer-Reviewed Original ResearchConceptsOpioid use disorderCOVID-19 testPrick testUse disordersCOVID-19Older aged participantsTesting measuresSaliva-based testThroat swab samplesCOVID-19 transmissionGreater proportionGreater riskSwab samplesAdverse effectsAged participantsTesting optionsDisadvantaged populationsRacial-ethnic minoritiesWhite participantsDemographic differencesDisordersHome ordersGreater rateTreatmentParticipants
2020
Response to the COVID-19 Outbreak in Urban Settings in China
Ni Z, Lebowitz ER, Zou Z, Wang H, Liu H, Shrestha R, Zhang Q, Hu J, Yang S, Xu L, Wu J, Altice FL. Response to the COVID-19 Outbreak in Urban Settings in China. Journal Of Urban Health 2020, 98: 41-52. PMID: 33258088, PMCID: PMC7703725, DOI: 10.1007/s11524-020-00498-8.Peer-Reviewed Original Research
2017
Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS And Behavior 2017, 22: 1228-1238. PMID: 28695388, PMCID: PMC5762432, DOI: 10.1007/s10461-017-1851-1.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSex-related risk behaviorsHigh-risk drug usersAcceptability of PrEPHigh-risk PWUDPrimary HIV preventionHIV prevention approachesDrug treatment settingsKey risk populationsHIV-negative PWUDHigh acceptabilityHIV clinicPrEP acceptabilityHIV testingPrEP uptakeMethadone clinicsHIV preventionRisk populationsSide effectsTreatment settingsDrug usersPrEP attributesRisk behaviorsPrEPUnderserved populations